Literature DB >> 11498784

p53 directs conformational change and translation initiation blockade of human fibroblast growth factor 2 mRNA.

B Galy1, L Créancier, L Prado-Lourenço, A C Prats, H Prats.   

Abstract

Tumour suppressor p53 has been shown to inhibit fibroblast growth factor 2 expression post-transcriptionally in cultured cells. Here we have investigated the mechanism responsible for this post-transcriptional blockade. Deletion mutagenesis of the FGF-2 mRNA leader revealed the requirement of at least four RNA cis-acting elements to mediate the inhibitory effect of p53 in SK-Hep-1 transfected cells, suggesting the involvement of RNA secondary or tertiary structures. Recombinant wild-type, but not Ala(143) mutant p53, was able to specifically repress FGF-2 mRNA translation in rabbit reticulocyte lysate, in a dose dependent manner. Sucrose gradient experiments showed that p53 blocks translation initiation by preventing 80S ribosome formation on an mRNA bearing the FGF-2 mRNA leader sequence. Interaction of wild-type and mutant p53 with different RNAs showed no significant correlation between p53 RNA binding activity and its translational inhibiting effect. However, by checking the accessibility of the FGF-2 mRNA leader to complementary oligonucleotide probes, we showed that the binding to RNA of wild-type, but not mutant p53, induced RNA conformational changes that might be responsible for the translational blockade. This strongly suggests that p53 represses FGF-2 mRNA translation by a direct mechanism involving its nucleic acid unwinding-annealing activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11498784     DOI: 10.1038/sj.onc.1204630

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

Review 1.  p53, a translational regulator: contribution to its tumour-suppressor activity.

Authors:  V Marcel; F Catez; J-J Diaz
Journal:  Oncogene       Date:  2015-03-02       Impact factor: 9.867

Review 2.  p53 RNA interactions: new clues in an old mystery.

Authors:  Kasandra J-L Riley; L James Maher
Journal:  RNA       Date:  2007-09-05       Impact factor: 4.942

3.  Analysis of p53-RNA interactions in cultured human cells.

Authors:  Kasandra J-L Riley; L James Maher
Journal:  Biochem Biophys Res Commun       Date:  2007-09-10       Impact factor: 3.575

4.  Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF.

Authors:  Gangjian Qin; Raj Kishore; Christine M Dolan; Marcy Silver; Andrea Wecker; Corinne N Luedemann; Tina Thorne; Allison Hanley; Cynthia Curry; Lindsay Heyd; Deepika Dinesh; Marianne Kearney; Fabio Martelli; Toshinori Murayama; David A Goukassian; Yan Zhu; Douglas W Losordo
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-11       Impact factor: 11.205

Review 5.  Regulation of tumor suppressor p53 at the RNA level.

Authors:  Anna Vilborg; Margareta T Wilhelm; Klas G Wiman
Journal:  J Mol Med (Berl)       Date:  2010-03-21       Impact factor: 4.599

6.  Chlamydia trachomatis co-opts the FGF2 signaling pathway to enhance infection.

Authors:  Jung Hwa Kim; Shaobo Jiang; Cherilyn A Elwell; Joanne N Engel
Journal:  PLoS Pathog       Date:  2011-10-06       Impact factor: 6.823

7.  Recognition of RNA by the p53 tumor suppressor protein in the yeast three-hybrid system.

Authors:  Kasandra J-L Riley; Laura A Cassiday; Akash Kumar; L James Maher
Journal:  RNA       Date:  2006-04       Impact factor: 4.942

8.  SIRT1 undergoes alternative splicing in a novel auto-regulatory loop with p53.

Authors:  Cian J Lynch; Zahid H Shah; Simon J Allison; Shafiq U Ahmed; Jack Ford; Lorna J Warnock; Han Li; Manuel Serrano; Jo Milner
Journal:  PLoS One       Date:  2010-10-21       Impact factor: 3.240

9.  RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player.

Authors:  K Häbig; M Walter; S Poths; O Riess; M Bonin
Journal:  Neurogenetics       Date:  2007-12-21       Impact factor: 2.660

10.  p53 binds the mdmx mRNA and controls its translation.

Authors:  A-S Tournillon; I López; L Malbert-Colas; S Findakly; N Naski; V Olivares-Illana; K Karakostis; B Vojtesek; K Nylander; R Fåhraeus
Journal:  Oncogene       Date:  2016-07-04       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.